Table 5.
Current biomarker-enriched preoperative clinical trials in pancreatic cancer
| Trial ID | Biomarker | Therapeutic drugs | Phase | Status |
|---|---|---|---|---|
| NCT04176952 | HRD signature | FOLFOX-A Gemcitabine/nab-paclitaxel |
II non-randomised | Recruiting |
| NCT04005690 | Multiple, not specified | Cobimetinib Olaparib |
II non-randomised | Recruiting |
| NCT04481204 | Multiple, not specified | Multiple drugs | II randomised | Not yet recruiting |
Clinical trials including (not limited to) patients with resectable/borderline resectable pancreatic cancer. FOLFOX-A: 5-fluorouracil/leucovorin, oxaliplatin, nab-paclitaxel.
DDR, DNA damage response; HRD, homologous recombination system deficiency.